Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions
Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the United States. Most patients will ultimately fail platinum-based chemotherapy and have the disease recur. Interest is increasing in the use of targeted therapies in the treatment of EOC. This review focuses on th...
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2018-03, Vol.40 (3), p.361-371 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 3 |
| container_start_page | 361 |
| container_title | Clinical therapeutics |
| container_volume | 40 |
| creator | Vetter, Monica Hagan Hays, John L. |
| description | Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the United States. Most patients will ultimately fail platinum-based chemotherapy and have the disease recur. Interest is increasing in the use of targeted therapies in the treatment of EOC. This review focuses on the current use of targeted therapeutics in EOC as well as future directions.
A literature search of Medline and PubMed was conducted (January 2000–October 2017) to identify recent reports of targeted drugs in EOC.
A wide range of targeted therapeutics is currently being used as both monotherapy and in combination in the treatment of EOC. Clinically, the most commonly used classes of drugs currently are antiangiogenics and poly (ADP-ribose) polymerase inhibitors. However, a number of drugs in varying stages in development target a wide range of biochemical pathways. Activity and response rates of these drugs vary greatly. Questions continue about combination drug therapy and appropriate patient selection.
The use of targeted therapeutics in the treatment of EOC, both as monotherapy and in combination, will continue to expand as more mechanisms of tumorigenesis are identified. Multiple clinical trials of a wide range of targeted therapeutics are currently ongoing. Evidence-based selection of drug targets and appropriate patient populations will allow strategic application of targeted therapeutics. |
| doi_str_mv | 10.1016/j.clinthera.2018.01.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2008884411</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291818300456</els_id><sourcerecordid>2014372010</sourcerecordid><originalsourceid>FETCH-LOGICAL-c399t-28572d0b7134532b2caa1bf58a2812df13d5b19124e6b59125b7cea3b851b3b83</originalsourceid><addsrcrecordid>eNqFkUFvEzEQhS0EomnhL4AlLlw2eGZ3uza3KLSAFKkSSiVulu2dBUcbb7C9Rfz7Ok3pgQvSaMaH781Y7zH2FsQSBFx-2C3d6EP-SdEsUYBcCiiFz9gCZKcqgOb7c7YQ0KgKFcgzdp7STghRqxZfsjNUjUSFuGDTbSI-DXxr4g_K1PPtceeB5uxd4j7wq4MvZ0ZvRn5zZ6I3ga9NcBQ_8hX_Rneefh_16zlGCplvfC76PEfiJvT8en54fvKRXPZTSK_Yi8GMiV4_zgt2e321XX-pNjefv65Xm8rVSuUKZdthL2wHddPWaNEZA3ZopUEJ2A9Q960FBdjQpW3LbG3nyNRWtmBLry_Y-9PeQ5x-zZSy3vvkaBxNoGlOGoWQUjYNQEHf_YPupjmG8rtCQVN3pYtCdSfKxSmlSIM-RL838Y8GoY-Z6J1-yuQolFpAKSzKN4_7Z7un_kn3N4QCrE4AFUOKoVEn56l43D_YpvvJ__fIPTgZoNM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2014372010</pqid></control><display><type>article</type><title>Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Vetter, Monica Hagan ; Hays, John L.</creator><creatorcontrib>Vetter, Monica Hagan ; Hays, John L.</creatorcontrib><description>Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the United States. Most patients will ultimately fail platinum-based chemotherapy and have the disease recur. Interest is increasing in the use of targeted therapies in the treatment of EOC. This review focuses on the current use of targeted therapeutics in EOC as well as future directions.
A literature search of Medline and PubMed was conducted (January 2000–October 2017) to identify recent reports of targeted drugs in EOC.
A wide range of targeted therapeutics is currently being used as both monotherapy and in combination in the treatment of EOC. Clinically, the most commonly used classes of drugs currently are antiangiogenics and poly (ADP-ribose) polymerase inhibitors. However, a number of drugs in varying stages in development target a wide range of biochemical pathways. Activity and response rates of these drugs vary greatly. Questions continue about combination drug therapy and appropriate patient selection.
The use of targeted therapeutics in the treatment of EOC, both as monotherapy and in combination, will continue to expand as more mechanisms of tumorigenesis are identified. Multiple clinical trials of a wide range of targeted therapeutics are currently ongoing. Evidence-based selection of drug targets and appropriate patient populations will allow strategic application of targeted therapeutics.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2018.01.012</identifier><identifier>PMID: 29482922</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Angiogenesis ; Angiogenesis Inhibitors - therapeutic use ; antiangiogenics ; Cancer therapies ; Carcinoma, Ovarian Epithelial - drug therapy ; Chemotherapy ; Clinical trials ; Drug dosages ; epithelial ovarian cancer ; Female ; Humans ; Kinases ; Literature reviews ; Medical prognosis ; Medical research ; Metastasis ; Molecular Targeted Therapy ; Neoplasm Recurrence, Local - drug therapy ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; PARP inhibitors ; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use ; Proteins ; targeted therapeutics ; Tumorigenesis ; Tumors ; Vascular endothelial growth factor</subject><ispartof>Clinical therapeutics, 2018-03, Vol.40 (3), p.361-371</ispartof><rights>2018 Elsevier HS Journals, Inc.</rights><rights>Copyright © 2018 Elsevier HS Journals, Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Mar 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c399t-28572d0b7134532b2caa1bf58a2812df13d5b19124e6b59125b7cea3b851b3b83</citedby><cites>FETCH-LOGICAL-c399t-28572d0b7134532b2caa1bf58a2812df13d5b19124e6b59125b7cea3b851b3b83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2014372010?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29482922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vetter, Monica Hagan</creatorcontrib><creatorcontrib>Hays, John L.</creatorcontrib><title>Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the United States. Most patients will ultimately fail platinum-based chemotherapy and have the disease recur. Interest is increasing in the use of targeted therapies in the treatment of EOC. This review focuses on the current use of targeted therapeutics in EOC as well as future directions.
A literature search of Medline and PubMed was conducted (January 2000–October 2017) to identify recent reports of targeted drugs in EOC.
A wide range of targeted therapeutics is currently being used as both monotherapy and in combination in the treatment of EOC. Clinically, the most commonly used classes of drugs currently are antiangiogenics and poly (ADP-ribose) polymerase inhibitors. However, a number of drugs in varying stages in development target a wide range of biochemical pathways. Activity and response rates of these drugs vary greatly. Questions continue about combination drug therapy and appropriate patient selection.
The use of targeted therapeutics in the treatment of EOC, both as monotherapy and in combination, will continue to expand as more mechanisms of tumorigenesis are identified. Multiple clinical trials of a wide range of targeted therapeutics are currently ongoing. Evidence-based selection of drug targets and appropriate patient populations will allow strategic application of targeted therapeutics.</description><subject>Angiogenesis</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>antiangiogenics</subject><subject>Cancer therapies</subject><subject>Carcinoma, Ovarian Epithelial - drug therapy</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Drug dosages</subject><subject>epithelial ovarian cancer</subject><subject>Female</subject><subject>Humans</subject><subject>Kinases</subject><subject>Literature reviews</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Metastasis</subject><subject>Molecular Targeted Therapy</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>PARP inhibitors</subject><subject>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</subject><subject>Proteins</subject><subject>targeted therapeutics</subject><subject>Tumorigenesis</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUFvEzEQhS0EomnhL4AlLlw2eGZ3uza3KLSAFKkSSiVulu2dBUcbb7C9Rfz7Ok3pgQvSaMaH781Y7zH2FsQSBFx-2C3d6EP-SdEsUYBcCiiFz9gCZKcqgOb7c7YQ0KgKFcgzdp7STghRqxZfsjNUjUSFuGDTbSI-DXxr4g_K1PPtceeB5uxd4j7wq4MvZ0ZvRn5zZ6I3ga9NcBQ_8hX_Rneefh_16zlGCplvfC76PEfiJvT8en54fvKRXPZTSK_Yi8GMiV4_zgt2e321XX-pNjefv65Xm8rVSuUKZdthL2wHddPWaNEZA3ZopUEJ2A9Q960FBdjQpW3LbG3nyNRWtmBLry_Y-9PeQ5x-zZSy3vvkaBxNoGlOGoWQUjYNQEHf_YPupjmG8rtCQVN3pYtCdSfKxSmlSIM-RL838Y8GoY-Z6J1-yuQolFpAKSzKN4_7Z7un_kn3N4QCrE4AFUOKoVEn56l43D_YpvvJ__fIPTgZoNM</recordid><startdate>201803</startdate><enddate>201803</enddate><creator>Vetter, Monica Hagan</creator><creator>Hays, John L.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>201803</creationdate><title>Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions</title><author>Vetter, Monica Hagan ; Hays, John L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c399t-28572d0b7134532b2caa1bf58a2812df13d5b19124e6b59125b7cea3b851b3b83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Angiogenesis</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>antiangiogenics</topic><topic>Cancer therapies</topic><topic>Carcinoma, Ovarian Epithelial - drug therapy</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Drug dosages</topic><topic>epithelial ovarian cancer</topic><topic>Female</topic><topic>Humans</topic><topic>Kinases</topic><topic>Literature reviews</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Metastasis</topic><topic>Molecular Targeted Therapy</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>PARP inhibitors</topic><topic>Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use</topic><topic>Proteins</topic><topic>targeted therapeutics</topic><topic>Tumorigenesis</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vetter, Monica Hagan</creatorcontrib><creatorcontrib>Hays, John L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest research library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vetter, Monica Hagan</au><au>Hays, John L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2018-03</date><risdate>2018</risdate><volume>40</volume><issue>3</issue><spage>361</spage><epage>371</epage><pages>361-371</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer death in the United States. Most patients will ultimately fail platinum-based chemotherapy and have the disease recur. Interest is increasing in the use of targeted therapies in the treatment of EOC. This review focuses on the current use of targeted therapeutics in EOC as well as future directions.
A literature search of Medline and PubMed was conducted (January 2000–October 2017) to identify recent reports of targeted drugs in EOC.
A wide range of targeted therapeutics is currently being used as both monotherapy and in combination in the treatment of EOC. Clinically, the most commonly used classes of drugs currently are antiangiogenics and poly (ADP-ribose) polymerase inhibitors. However, a number of drugs in varying stages in development target a wide range of biochemical pathways. Activity and response rates of these drugs vary greatly. Questions continue about combination drug therapy and appropriate patient selection.
The use of targeted therapeutics in the treatment of EOC, both as monotherapy and in combination, will continue to expand as more mechanisms of tumorigenesis are identified. Multiple clinical trials of a wide range of targeted therapeutics are currently ongoing. Evidence-based selection of drug targets and appropriate patient populations will allow strategic application of targeted therapeutics.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29482922</pmid><doi>10.1016/j.clinthera.2018.01.012</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2018-03, Vol.40 (3), p.361-371 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2008884411 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Angiogenesis Angiogenesis Inhibitors - therapeutic use antiangiogenics Cancer therapies Carcinoma, Ovarian Epithelial - drug therapy Chemotherapy Clinical trials Drug dosages epithelial ovarian cancer Female Humans Kinases Literature reviews Medical prognosis Medical research Metastasis Molecular Targeted Therapy Neoplasm Recurrence, Local - drug therapy Ovarian cancer Ovarian Neoplasms - drug therapy PARP inhibitors Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use Proteins targeted therapeutics Tumorigenesis Tumors Vascular endothelial growth factor |
| title | Use of Targeted Therapeutics in Epithelial Ovarian Cancer: A Review of Current Literature and Future Directions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T11%3A07%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Targeted%20Therapeutics%20in%20Epithelial%20Ovarian%20Cancer:%20A%20Review%20of%20Current%20Literature%20and%20Future%20Directions&rft.jtitle=Clinical%20therapeutics&rft.au=Vetter,%20Monica%20Hagan&rft.date=2018-03&rft.volume=40&rft.issue=3&rft.spage=361&rft.epage=371&rft.pages=361-371&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2018.01.012&rft_dat=%3Cproquest_cross%3E2014372010%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2014372010&rft_id=info:pmid/29482922&rft_els_id=S0149291818300456&rfr_iscdi=true |